High Affinity Nanobody Like Heavy Chain Variable Domains (VHHs) Targeting C-terminal of Mesothelin (MSLN)
This innovation is presented on behalf of Delaware State University through the University of Delaware's Technology Transfer Office. This invention holds potential as a precision carrier for targeted TNBC therapeutic delivery, a versatile platform for advancing cancer immunotherapy, and a valuable diagnostic tool.
Technology
Triple-negative breast carcinomas (TNBC) represent an aggressive subtype of breast cancer defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. Unlike other breast cancer subtypes, TNBC lacks specific molecular targets for endocrine or HER2-directed therapies, leaving patients reliant on conventional chemotherapy regimens. The clinical course of TNBC is often marked by early metastasis, high recurrence rates, and short survival following the first metastatic event. Consequently, there is an urgent and unmet clinical need to identify novel molecular targets and develop effective targeted therapies tailored for TNBC.
One emerging promising target is Mesothelin (MSLN) a tumor-associated antigen for immunotherapeutic targeting. MSLN is a glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein that is minimally expressed in normal mesothelial cells but is highly overexpressed in TNBC. This overexpression has been functionally implicated in tumor aggressiveness and can promote cancer progression through activation of several oncogenic signaling pathways. Despite being a promising therapeutic target, efforts to inhibit MSLN have encountered several challenges. One of the major limitations arises from MSLN shedding, where proteolytic cleavage of the C-terminal epitope results in the release of soluble mesothelin into the tumor microenvironment and circulation. This shedding can limit their efficacy. Therefore, designing antibodies that specifically recognize the C-terminal epitope has become an important strategy to inhibit MSLN shedding and ensure selective targeting of membrane-bound tumor cells.
Delaware State University (DSU) researchers have sought to overcome this hurdle. DSU researchers have computationally designed nanobody-like heavy chain variable domains (VHHs) that bind the C-terminal region of MSLN, which showed strong binding affinities comparable to full-length antibodies in vitro. Some nanobody designs also demonstrated binding to MSLN-expressing TNBC cell line. Unlike full-sized mAbs, which often suffer from poor tissue penetration and immunogenicity, nanobodies offer a lower immunogenic profile and better pharmacokinetic behavior due to their high similarity to human VH3 germline sequences. Additionally, nanobodies have a compact size and can show high specificity and affinity with excellent solubility, thermal stability, and deep tissue penetration. Their simple architecture allows for expression in bacterial systems, rapid engineering, and flexible conjugation to therapeutic or diagnostic moieties. These VHHs could be used as targeted therapeutics for TNBC. These VHHs specifically bind to the C-terminal domain of MSLN, which prevents its shedding and ensures selective targeting of membrane-bound tumor cells. This invention holds potential as a precision carrier for targeted TNBC therapeutic delivery, a versatile platform for advancing cancer immunotherapy, and a valuable diagnostic tool for detecting TNBC, enhancing both treatment efficacy and early disease identification
Benefits
-
Selective targeting of MSLN, a potential therapeutic and diagnostic tool for patients with TNBC
-
Inhibit MSLN shedding
-
Lower immunogenic profile
-
Better pharmacokinetic behavior
-
High specificity and affinity with excellent solubility, thermal stability, and deep tissue penetration
-
Their simple architecture allows for expression in bacterial systems, rapid engineering, and flexible conjugation to therapeutic or diagnostic moieties.
Applications
-
Pharmaceutical & Biotechnology Industry
-
Diagnostics & Medical Imaging
-
Agricultural & Food Industry
-
Defense & Bioterrorism Countermeasures